Unilever’s Gina Boswell talks with DSNTV about ‘premiumizing’ the portfolio and upcoming innovation
Developing multi-tasking products for today’s busy consumers and launching regimen innovation to make the beauty aisles easier to navigate are just a few ways in which Unilever is looking to better meet the needs of its consumers and retail partners. To discuss these initiatives and more, DSNTV recently interviewed Gina Boswell of Unilever for its Executive Viewpoint video series.
Menasha Packaging Co.’s Paul Murphy discusses navigating the Rx-to-OTC switch
Rx-to-OTC switches are expected to continue, serving as a triple-win for the industry as retailers gain more store traffic and category sales; consumers benefit from easier access to effective remedies; and brands enjoy revenue streams that extend beyond patent expiration.
To help industry players better navigate the challenges within the complex Rx-to-OTC process and share insights into the best switch scenarios, DSNTV recently interviewed Paul Murphy of Menasha Packaging Co. for its Executive Viewpoint video series.
Ohm Labs to launch valsartan tabs
NEW BRUNSWICK, N.J. — Ohm Labs, a wholly owned subsidiary of Ranbaxy Labs, on Friday announced that it received approval from the Food and Drug Administration to manufacture and market valsartan tablets in 40 mg, 80 mg, 160 mg and 320 mg dosage strengths.
The drug, a generic version of Diovan from Novartis, is used for the treatment of high blood pressure and heart failure. Sales for Diovan totalled $2.19 billion for the 12 months ending April 2014, according to IMS data.
“We have been anticipating marketing approval of Valsartan for some time, now; and we are very pleased that this has finally come to fruition," Bill Winter, VP sales and distribution, North America, said. "For us, it represents our continuing resolve to bring high quality, affordable medicines to patients and prescribers. For the U.S. healthcare system, Valsartan adds to the growing portfolio of generic medications which have played such an integral role in helping to alleviate the burdens of rising costs of treatment.”